Author

W. Zhang

Institution: Sanofi (United States)

Observed institution: Sanofi (United States)

OpenAlex ID: A5083197028

PROSELICA: Health-related quality of life (HRQL) and post-hoc analyses for the phase 3 study assessing cabazitaxel 20 (C20) vs 25 (C25) mg/m2 post-docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

2016 · J.S. de Bono, A.-C. Hardy-Bessard, et al. · Annals of Oncology · 4

Assessment of health-related quality of life (HRQL) in PROSELICA: A Phase 3 trial assessing cabazitaxel 20 mg/m2 (C20) vs 25 mg/m2 (C25) in post-docetaxel (D) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

2017 · M. Eisenberger, A-C. Hardy-Bessard, et al. · Annals of Oncology

Works count: 2

Citation count: 4

H-index: 1

I10-index: